Literature DB >> 16254701

Modulating processes within the central nervous system is central to therapeutic control of multiple sclerosis.

Tjalf Ziemssen1.   

Abstract

Historically considered to be an autoimmune demyelinating disease, multiple sclerosis is now recognized to be characterized by significant axonal and neuronal pathology. Addressing this neurodegenerative component of the disease is an important treatment objective, since axonal injury is believed to underlie the accumulation of disability and disease progression. The precise relationship between the inflammatory and neurodegenerative components in multiple sclerosis remains poorly elucidated, although neurodegeneration appears to be at least partially independent from neuroinflammation. The mechanisms underlying axonal injury appear complex and are likely to be multifactorial. Specific treatment strategies need to be developed that act within the central nervous system to prevent neurodegeneration and need to be provided from the earliest stages of disease. It is likely that immunomodulatory treatments acting purely in the periphery will provide only indirect and not direct neuroprotection. A promising approach is to enhance neuroprotective autoimmunity inside the brain, believed to be mediated, at least in part, by the release of neurotrophic factors within the nervous system from infiltrating immune cells. Such a beneficial process would be inhibited by a non-selective immunosuppressive strategy. In summary, treatments of multiple sclerosis should take into account the heterogeneous pathophysiology of the disease. The pathogenic process in the central nervous system itself should be the major focus in multiple sclerosis therapy in order to protect against demyelination and axonal loss and to promote remyelination and regeneration directly in the target tissue, independently of peripheral immune status. In conclusion, selective treatment strategies aimed at preventing axonal injury within the central nervous system are required to complement existing, peripherally acting treatments targeting the immune system.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16254701     DOI: 10.1007/s00415-005-5007-2

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  42 in total

1.  LIF receptor signaling limits immune-mediated demyelination by enhancing oligodendrocyte survival.

Authors:  Helmut Butzkueven; Jian-Guo Zhang; Merja Soilu-Hanninen; Hubertus Hochrein; Fiona Chionh; Kylie A Shipham; Ben Emery; Ann M Turnley; Steven Petratos; Matthias Ernst; Perry F Bartlett; Trevor J Kilpatrick
Journal:  Nat Med       Date:  2002-06       Impact factor: 53.440

Review 2.  Neuroprotection and glatiramer acetate: the possible role in the treatment of multiple sclerosis.

Authors:  Tjalf Ziemssen
Journal:  Adv Exp Med Biol       Date:  2004       Impact factor: 2.622

3.  Tumor necrosis factor blockade in actively induced experimental autoimmune encephalomyelitis prevents clinical disease despite activated T cell infiltration to the central nervous system.

Authors:  H Körner; F A Lemckert; G Chaudhri; S Etteldorf; J D Sedgwick
Journal:  Eur J Immunol       Date:  1997-08       Impact factor: 5.532

4.  Cutting edge: clonally restricted production of the neurotrophins brain-derived neurotrophic factor and neurotrophin-3 mRNA by human immune cells and Th1/Th2-polarized expression of their receptors.

Authors:  M Besser; R Wank
Journal:  J Immunol       Date:  1999-06-01       Impact factor: 5.422

5.  BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells?

Authors:  Christine Stadelmann; Martin Kerschensteiner; Thomas Misgeld; Wolfgang Brück; Reinhard Hohlfeld; Hans Lassmann
Journal:  Brain       Date:  2002-01       Impact factor: 13.501

6.  The neuregulin, glial growth factor 2, diminishes autoimmune demyelination and enhances remyelination in a chronic relapsing model for multiple sclerosis.

Authors:  B Cannella; C J Hoban; Y L Gao; R Garcia-Arenas; D Lawson; M Marchionni; D Gwynne; C S Raine
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-18       Impact factor: 11.205

7.  Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration.

Authors:  L Bø; C A Vedeler; H Nyland; B D Trapp; S J Mørk
Journal:  Mult Scler       Date:  2003-08       Impact factor: 6.312

8.  Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor.

Authors:  Tjalf Ziemssen; Tania Kümpfel; Wolfgang E F Klinkert; Oliver Neuhaus; Reinhard Hohlfeld
Journal:  Brain       Date:  2002-11       Impact factor: 13.501

9.  Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation?

Authors:  M Kerschensteiner; E Gallmeier; L Behrens; V V Leal; T Misgeld; W E Klinkert; R Kolbeck; E Hoppe; R L Oropeza-Wekerle; I Bartke; C Stadelmann; H Lassmann; H Wekerle; R Hohlfeld
Journal:  J Exp Med       Date:  1999-03-01       Impact factor: 14.307

10.  Human nerve growth factor protects common marmosets against autoimmune encephalomyelitis by switching the balance of T helper cell type 1 and 2 cytokines within the central nervous system.

Authors:  P Villoslada; S L Hauser; I Bartke; J Unger; N Heald; D Rosenberg; S W Cheung; W C Mobley; S Fisher; C P Genain
Journal:  J Exp Med       Date:  2000-05-15       Impact factor: 14.307

View more
  9 in total

1.  [Multiple sclerosis. An update with practical guidelines for ophthalmologists].

Authors:  T Ziemssen; H Wilhelm; F Ziemssen
Journal:  Ophthalmologe       Date:  2006-07       Impact factor: 1.059

2.  Evaluation of a transgenic mouse model of multiple sclerosis with noninvasive methods.

Authors:  Mabel Enriquez-Algeciras; Di Ding; Tsung-Han Chou; Jianhua Wang; Kyle R Padgett; Vittorio Porciatti; Sanjoy K Bhattacharya
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-04-14       Impact factor: 4.799

Review 3.  Inflammation, demyelination, neurodegeneration and neuroprotection in the pathogenesis of multiple sclerosis.

Authors:  Lisa K Peterson; Robert S Fujinami
Journal:  J Neuroimmunol       Date:  2006-12-28       Impact factor: 3.478

Review 4.  Spontaneous ocular and neurologic deficits in transgenic mouse models of multiple sclerosis and noninvasive investigative modalities: a review.

Authors:  Archana A Gupta; Di Ding; Richard K Lee; Robert B Levy; Sanjoy K Bhattacharya
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-02-13       Impact factor: 4.799

Review 5.  Alzheimer's disease; taking the edge off with cannabinoids?

Authors:  V A Campbell; A Gowran
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

Review 6.  Neurogenesis and neuroprotection in the CNS--fundamental elements in the effect of Glatiramer acetate on treatment of autoimmune neurological disorders.

Authors:  Ruth Arnon; Rina Aharoni
Journal:  Mol Neurobiol       Date:  2007-10-11       Impact factor: 5.590

7.  Deimination restores inner retinal visual function in murine demyelinating disease.

Authors:  Mabel Enriquez-Algeciras; Di Ding; Fabrizio G Mastronardi; Robert E Marc; Vittorio Porciatti; Sanjoy K Bhattacharya
Journal:  J Clin Invest       Date:  2013-01-02       Impact factor: 14.808

8.  What can we learn from failed clinical trials in multiple sclerosis?

Authors:  Tjalf Ziemssen
Journal:  J Neurol       Date:  2008-12       Impact factor: 4.849

9.  Dopaminergic Receptor Targeting in Multiple Sclerosis: Is There Therapeutic Potential?

Authors:  Mikhail Melnikov; Mikhail Pashenkov; Alexey Boyko
Journal:  Int J Mol Sci       Date:  2021-05-18       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.